Stock AnalizStoke Therapeutics, Inc. STOK
Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026
Stoke Therapeutics, Inc. (STOK) is a healthcare company listed in the US with a market value of about $1.7B. In the twelve months to September 30, 2026 it had revenue of $28M and net income of -$243M, a net margin of -862.1%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -33%.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $28M | $184M | $37M | $9M | $12M | — | — | — | — |
| Net income | -$243M | -$7M | -$89M | -$105M | -$101M | -$86M | -$52M | -$32M | -$13M |
| Free cash flow | -$216M | $45M | -$87M | -$83M | -$36M | -$68M | -$43M | -$33M | -$12M |
| EPS (diluted) | $-3.77 | $-0.12 | $-1.65 | $-2.38 | $-2.60 | $-2.34 | $-1.56 | $-1.80 | $-17.65 |
| Net margin | -862.1% | -3.7% | -243.4% | -1192.5% | -814.7% | — | — | — | — |
| ROIC | — | -4.6% | -34.2% | -54.5% | -43.4% | -30.2% | -14.6% | -12.6% | -9.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $46.38, 74% above the current price; targets range from $35.00 to $60.00; the consensus rating is “Strong buy”; expected EPS is $-4.01 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Stoke Therapeutics pay a dividend?
Not currently.
Is Stoke Therapeutics a good stock to buy?
We do not give buy or sell advice. Stoke Therapeutics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.